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vastatin had no effect on the incidence or severity of acuteEffect of fluvastatin on acute renal allograft rejection: A ran-
rejection following renal transplantation. There were no in-domized multicenter trial.
creases in adverse events. A significant and potentially benefi-Background. Statin therapy has been reported to reduce the
cial alteration in the lipid profile was observed in the earlyacute rejection rate following renal transplantation in a pilot
post transplant period. We conclude that fluvastatin may bestudy. The present study is the first randomized, double-blind
used safely to correct dyslipidemia in patients with end-stageand adequately powered study to examine the effect of statins
renal failure through the peri-transplant period.on acute rejection of renal allografts.
Methods. A total of 364 patients were randomly assigned to
receive either fluvastatin 40 mg or placebo in combination with
conventional cyclosporine-based immunosuppressive therapy. HMG–CoA (3,hydroxy, 3-methylglutaryl coenzyme A)The primary end point was treated first acute rejection. Second-
reductase inhibitor (statin) therapy is of proven benefitary end points included biopsy-proven rejection, histological se-
in reducing cardiovascular morbidity and mortality inverity of rejection, occurrence of steroid-resistant rejection,
and serum creatinine at three months following transplanta- patients with or without coronary disease (CVD) [1–6].
tion. However, there is some evidence that certain effects of
Results. Fluvastatin was well tolerated; no patients developed these drugs, including beneficial effects in patients withmyositis or rhabdomyolysis. There was no difference in the
osteoporosis [7–10], are independent of cholesterol re-acute rejection rate [86 (47.3%) fluvastatin vs. 87 (47.8%) pla-
duction and may be due to the reduced synthesis of othercebo] and no significant difference in the severity of rejection,
steroid resistant rejection or mean serum creatinine at three isoprenoid products of the mevalonate pathway [7, 8].
months (160 mol/L vs. 160 mol/L). Total cholesterol, low- The putative potential effects on osteoporosis, however,
density lipoprotein (LDL) and high-density lipoprotein (HDL) have recently been challenged [11]. Four pilot studiescholesterol and triglyceride levels increased following renal
have examined the effects of statin treatment in solidtransplantation. With the exception of the increase in HDL-C,
organ transplant populations. In kidney recipients a sig-which was augmented, the increases in lipid parameters were
significantly reduced by fluvastatin (total cholesterol 17.5% nificant reduction in the rejection rate was observed [12].
vs. 35.7%; LDL-C 6.3% vs. 46.7%; HDL-C 43.3% vs. Two studies in heart transplant recipients have reported
38.1%; triglyceride 52.2% vs 77.6%). conflicting results. Wencke et al could not demonstrateConclusions. Contrary to the reported effects of statins, flu-
any significant effect on rejection rates in a four-year
follow-up study [13]. In the study of Kobashigawa et al,
an effect was only evident for severe rejections withKey words: kidney transplantation, acute rejection, HMG CoA reduc-
tase inhibition, dyslipidemia, end-stage renal failure, cyclosporine A. hemodynamic compromise, whereas statin treatment
had no effect on mild or moderate rejection episodesReceived for publication March 28, 2001
[14]. Recently a multicenter placebo-controlled study,and in revised form June 18, 2001
Accepted for publication June 20, 2001 including simvastatin in one arm, failed to demonstrate
any effect of simvastatin on acute renal allograft rejec- 2001 by the International Society of Nephrology
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tion (Kasiske et al, Transplantation 69:S225, 2000). Stud- used. The use of antibody therapy, mycophenolate or
tacrolimus was precluded at the outset, although subse-ies in experimental animals also have shown prolonga-
tion of islet and cardiac allograft survival associated with quent changes in therapy for clinical indications, such as
acute rejection, were at the discretion of the investigatingstatin treatment [15, 16]. The explanation for these obser-
vations has focused on the effects of statins on the func- physician. The protocol was approved by the national
and local ethical committees in the participating centerstion of leukocytes and the observation that inhibition
of the production of specific isoprenoids—farnesyl and in Norway, Sweden, Finland, United Kingdom and Ire-
land. The study was carried out according to the Declara-geranylgeranyl—might inhibit proliferation of T lympho-
cytes and natural killer (NK) cells in vitro [7, 17–20]. tion of Helsinki. All patients gave written informed con-
sent to participate, and were recruited prior to, or withinRecently, it has been demonstrated that statins might
inhibit the inducible expression of the class II major 48 hours of transplantation surgery.
histocompatibility complex and thus repress activation
Study designof T cells in the immune response [21]. Preliminary find-
ings in human transplant recipients suggest that statins Fluvastatin, 40 mg per day (or placebo), was adminis-
tered in a double-blind fashion for twelve weeks follow-may also reduce NK cell function in vivo [12, 14, 15].
Taken together, while these studies suggest a potential ing transplantation. Blood samples were taken for fasting
lipids, serum creatinine and full blood count at recruit-mechanism for statin-mediated immunosuppression, in
the absence of adequately powered studies, it remains ment and 2, 6 and 12 weeks after commencement of ther-
apy. A central laboratory (Medinet, Breda, The Neth-uncertain whether this effect is of any clinical relevance.
Hyperlipidemia is common in renal transplant recipi- erlands) was assigned to analyze all serum lipids and
selective biochemical parameters.ents (RTR), with levels of cholesterol and triglyceride
increasing in the early post-transplant period, and is The primary end point was treated acute rejection,
defined as a clinically suspected acute rejection episode,likely to contribute to increased cardiovascular risk [22,
23, 24]. Thus, there is considerable interest in the use of during which the patient completed a course of high-
dose steroids according to the local protocol. There werestatins in this population. Fluvastatin has potential bene-
fits in the treatment of hyperlipidemia in organ trans- no stipulations on the treatment either for subsequent
rejection episodes, or for changes in immunosuppressiveplantation [25, 26, 27] and it does not share a metabolic
pathway with the calcineurin inhibitors cyclosporine and therapy deemed appropriate following the first acute
rejection episode. The study protocol required biopsytacrolimus. Inhibition of the microsomal enzyme cyto-
chrome P450 3A4 (CyP 3A4) by these immunosuppres- confirmation where possible. All biopsies were scored by
an experienced renal histopathologist according to thesive agents inhibits the metabolism of statins. The increase
in fluvastatin concentration by calcineurin inhibitors is Banff criteria [28]. In addition to the primary end point,
secondary end points were studied. These included biopsy-therefore less than that observed with other statins.
Thus, the present study was designed to assess the effects proven rejection, histological severity of rejection, the
number of steroid resistant rejection episodes, graft loss,of administration of fluvastatin on acute rejection in
RTR receiving cyclosporine-based immunosuppressive serum creatinine at three months, absolute lipid levels,
and lipid sub-fractions. Sequentially numbered sets of studyregimes.
medication were made available to each clinical site.
Each medication pack was labeled with a study identifi-
METHODS
cation code and randomization number. Randomization
Patients was stratified by center and blocked pseudorandomiza-
tion was performed by the producer centrally (Switzer-This study was an international, multicenter, random-
ized, double-blind, placebo controlled trial of fluvastatin land). The block size was eight patients. Following ran-
domization, patients were assigned a unique patient40 mg daily or matched placebo in RTR. All patients
aged 18 years or older, receiving cadaveric or living re- identifier consisting of a center number and a patient
number. Center numbers were assigned centrally andlated renal allografts, were eligible. Multiorgan trans-
plant recipients were excluded, but patients receiving a patient numbers by the investigator. Patients received
medication according to randomization number: patientssecond or subsequent renal allograft were eligible for
inclusion. The protocol also excluded patients with ma- with a cadaveric donor graft were assigned the next avail-
able randomization number starting from the beginning,lignant disease, serological evidence of HIV or HbsAg,
systemic infection, pregnancy, or those using inadequate patients with a living donor graft were assigned the next
available number starting from the end of the list ofcontraceptive measures. All patients received cyclospo-
rine-based immunosuppressive regimes, including pre- available randomized numbers. All study personnel di-
rectly involved in the conduct of the study were blindeddnisolone with, or without, azathioprine. There were no
stipulations on the dosages of immunosuppressive agents to treatment until all patients had completed the study
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and all data were finalized. Randomization was centrally Eighty-three percent of the patients who commenced
the study completed the full protocol, with no differenceperformed using a validated system that automates the
random assignment of treatment groups to randomiza- between groups. The reasons for withdrawal, including
seven deaths, are outlined in Table 2, and did not differtion numbers. Randomization data were kept strictly
confidential, accessible only to authorized persons, until between groups.
the time of unblinding.
Efficacy analysis
Statistical analysis Acute rejection. In the intention-to-treat analysis, 86
(47.3%) patients had a treated acute rejection episodeThe planned sample size was based on the assumption
that fluvastatin would reduce the incidence of first-treated compared with 87 (47.8%) in the placebo group (P 
0.92; Table 3). There was no difference in the mean timerejection episodes by 30%, from 45% in the placebo
group to 31.5% in the fluvastatin-treated group. Four- to first acute rejection [19 (17) vs. 18 (12) days]. The
first rejection episode was biopsy-confirmed in 70 and 75hundred-and-four patients were required without adjust-
ments for drop outs, with 5% alpha level and power  patients, respectively, and was deemed steroid resistant
(necessitating change to, or addition of, second-line im-80%. Due to administrative reasons, the trial was stopped
when 364 randomized and evaluable patients were com- munosuppression) in 38 (20.9%) patients in the fluvas-
tatin group and 34 (18.7%) in the placebo group (P pleted. With this number we could detect a 31.5% rela-
tive reduction in incidence, still with 80% power. The 0.44). Eighteen patients (9.9%) in the fluvastatin group,
and 19 (10.4%) in the placebo group (P  0.86) experi-primary efficacy analyses were based on intention-to-
treat for all variables. All patients who received at least enced a second acute rejection episode. The correspond-
ing numbers of graft losses (including death with a func-one dose of study medication were included. Per protocol
analyses also were performed for those patients who tioning graft) were 12 and 7, respectively (P  0.33).
The spectrum of histological severity is shown in Table 3.completed the trial on study medication. Descriptive sta-
tistics are given as mean (SD) for continuous variables There was a trend towards a smaller number of biopsies
with mild rejection in the fluvastatin group, althoughand number of cases (%) for the categorized variables.
The Chi-square or Fisher exact tests were used to com- this failed to achieve statistical significance (P  0.09).
Finally, there was no difference in graft function at threepare such variables between the two treatment groups.
The Cochran-Mantel-Haenzel test was used to compare months following transplantation. The serum creatinine
was 160  62 mol/L in the fluvastatin group and 160 categorical variables.
The primary end point comparison was a pre-planned 83 mol/L in the placebo group, in those patients whose
grafts continued to function at this time point.test for the difference between the Kaplan-Meier esti-
mates of not having a primary event within three months Lipid levels. It is well established that levels of total cho-
lesterol TC, low-density lipoprotein-cholesterol (LDL-C)in the two treatment groups. Comparison of changes in
the lipid values between baseline and three-month visits and high-density lipoprotein-cholesterol (HDL-C) rise
following transplantation as a result of immunosuppres-was done by calculating the mean of individual absolute
and percentage differences with confidence limits. sive therapy and altered diet [22–24]. Thus, the effects of
statins must be viewed against the changing background.
The absolute levels of TC, LDL-C, triglycerides (TG)
RESULTS
and HDL-C are shown in Table 4, and the mean values
Study population for LDL-cholesterol throughout the study period in Fig-
ure 1. There was a 17.5 (11.5 to 23.4)% increase (mean,A total of 364 patients (260 males) were recruited
between January 1998 and June 1999 in 11 centers in four 95% confidence interval) in total cholesterol in the flu-
vastatin group, compared with 35.7 (28.7 to 42.8)% in-European countries (147 UK, 97 Norway, 68 Sweden,
40 Finland, 12 Ireland). Eighty-seven patients received crease in the controls. The final total cholesterol at 12
weeks was 10.0% lower in the active treatment group.living donor transplants and 277 cadaveric transplants.
Demographic data are shown in Table 1. The mean age LDL-C showed a similar pattern. There was a 6.3 (0.09,
12.7)% increase in the fluvastatin group and a 46.7 (29.0,was 48.4 (14.1) years, 92.6% of patients were of Cauca-
sian origin and 12% had diabetes. The mean time on 64.5)% increase in the placebo group with the final
LDL-C being 18.2 lower in the active treatment group.renal replacement therapy was around three years, and
8% of patients had previously received a renal trans- HDL-C also increased following transplantation; the in-
crease in the treatment group was 43.3 (34.8 to 51.9)%plant. There was no difference in any of these parameters
between the two groups. The pattern of primary renal versus 38.1 (29.6 to 46.6)% in the control group. At 12
weeks the HDL-C was 6.1% higher in the active treat-disease, cytomegalovirus (CMV) status, donor age, cold
ischaemia and cross-match information also was similar ment group. Triglyceride levels were higher following
transplantation with a trend towards a smaller increase(Table 1).
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Table 1. Demographic details by treatment group
Demographic variable Fluvastatin Placebo Total P value
N 182 182 364
Age years 49.1 (13.5) 47.7 (14.8) 48.4 (14.1) 0.366
Sex 1.000
Male 130 (71.4%) 130 (71.4%) 260 (71.4%)
Female 52 (28.6%) 52 (28.6%) 104 (28.6%)
Race 0.548
Caucasian 167 (91.8%) 170 (93.4%) 337 (92.6%)
Black 5 (2.7%) 6 (3.3%) 11 (3.0%)
Asian/Oriental 5 (2.7%) 2 (1.1%) 7 (1.9%)
Other 5 (2.7%) 4 (2.2%) 9 (2.5%)
Weight kg 74.7 (13.6) 73.6 (14.3) 74.1 (14.0) 0.458
Primary cause of end-stage renal failure
Glomerulonephritis 46 (25.3%) 60 (33.0%) 106 (29.1%)
Chronic pyelonephritis 7 (3.8%) 7 (3.8%) 14 (3.8%)
Reflux/obstructive nephropathy 7 (3.8%) 11 (6.0%) 18 (4.9%)
Polycystic disease 35 (19.2%) 28 (15.4%) 63 (17.3%)
Hypertensive nephrosclerosis 23 (12.6%) 13 (7.1%) 36 (9.9%)
Diabetic nephropathy 18 (9.9%) 18 (9.9%) 36 (9.9%)
Other 46 (25.2%) 43 (23.5%) 89 (24.4%)
Total time on renal replacement therapy days 786 (881) 1018 (1609) 905 (1310)
Previous renal transplant 12 (6.6%) 17 (9.3%) 29 (8.0%)
Diabetes 20 (11.0%) 25 (13.7%) 45 (12.4%)
Donor age years 44.5 (15.8) 45.9 (15.0) 45.2 (15.4) 0.647
Donor recipient cytomegalovirus status
Positive Positive 83 (45.6%) 77 (42.3%) 160 (44.0%) 0.314
Positive Negative 30 (16.5%) 36 (19.8%) 66 (18.1%)
Negative Positive 43 (23.6%) 33 (18.1%) 76 (20.9%)
Negative Negative 23 (12.6%) 32 (17.6%) 55 (15.1%)
Donor recipients HLA-DR mismatches 0.594
0 59 (32.4%) 59 (32.4%) 118 (32.4)
1 96 (52.7%) 97 (53.3%) 193 (53.0%)
2 25 (13.7%) 18 (9.9%) 43 (11.8%)
Status of panel reactive antibodies 0.624
Positive 21 (11.5%) 18 (9.9%) 39 (10.7%)
Negative 161 (88.5%) 163 (89.6%) 324 (89.0%)
Donor specific B-cell crossmatch (Fisher test) 0.214
Positive 5 (2.7%) 1 (0.5%) 6 (1.6%)
Negative 157 (86.3%) 160 (87.9%) 317 (87.1%)
Donor specific T-cell crossmatch (Fisher test) 1.000
Positive 2 (1.1%) 1 (0.5%) 3 (0.8%)
Negative 180 (98.9%) 180 (98.9%) 360 (98.9%)
Cold ischemia time hours 18.9 (6.2) 20.2 (7.0) 19.5 (6.6) 0.170
Data are shown as number (% total). Continuous variable data are shown as mean (SD). See text for details.
Table 2. Patient disposition
Table 3. End points by treatment group
Fluvastatin Placebo
Fluvastatin PlaceboIntent-to-treat 182 (100%) 182 (100%)
End point (N182) (N182) P valueCompleted 151 (83.0%) 150 (82.4%)
Discontinued 30 (16.5%) 32 (17.6%) First treated rejection 86 (47.3%) 87 (47.8%) 0.916
Death 5 (2.7%) 2 (1.1%) Time to first treated
Adverse event 5 (2.7%) 6 (3.3%) rejection days 19.0 (17.2) 17.8 (12.1) 0.556
Withdrawn consent 3 (1.6%) 7 (3.8%) First steroid-resistant
Failure to return for scheduled visits 1 (0.5%) 0 (0.0%) rejection 38 (20.9%) 34 (18.7%) 0.442
Other 16 (8.8%) 16 (8.8%) First biopsy-confirmed
rejection 70 (38.5%) 75 (41.2%) 0.579
Second rejection episode 18 (9.9%) 19 (10.4%) 0.861
Graft loss or death 12 (6.6%) 7 (3.8%) 0.220
Biopsy-confirmed rejection,
graft loss or death 77 (42.3%) 80 (44.0%) 0.741in the fluvastatin group. The increase was 52.2 (37.0 to
Severity of rejection67.4)% in the active group compared with 77.6 (57.7 to (BANFF) 0.091
97.5)%, the levels at 12 weeks being 8.5% lower in the Mild (I) 26 (14.3%) 42 (23.1%)
Moderate (II) 36 (19.8%) 27 (14.8%)active treatment group.
Severe (III) 8 (4.4%) 6 (3.3%)Adverse events. There was a high incidence of adverse Serum creatinine at week 12 159.6 (62.2) 160.2 (83.0) 0.947
events in both groups consistent with the expected clini-
Data are shown as number (% total). Continuous variable data are shown as
mean (SD).cal course in the early post-transplant period (Table 5).
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Table 4. Lipid effects by treatment group
Baseline 12 weeks
Difference Difference %
Parameter Fluvastatin Placebo Fluvastatin Placebo FluvastatinPlacebo FluvastatinPlacebo
TC mmol/L 4.770.10 4.740.11 5.470.11 6.080.11 0.73 (1.08, 0.37) 18.3 (27.4, 9.11)
P0.001 P0.001
LDL-C mmol/L 2.990.08 2.960.09 3.060.08 3.740.10 0.84 (1.12, 0.56) 40.5 (59.0, 21.9)
P0.001 P0.001
HDL-C mmol/L 1.020.03 1.020.04 1.400.04 1.320.03 0.08 (0.03, 0.19) 5.23 (6.75, 17.2)
PNS PNS
TG mmol/L 1.680.08 1.550.07 2.040.09 2.240.09 0.30 (0.57, 0.02) 25.4 (50.2, 0.53)
P0.034 P0.046
Abbreviations are: TC, total cholesterol; LDL-C, low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol; TG, triglycerides.
Table 5. Adverse events by treatment group
Fluvastatin Placebo
Event (N182) (N182)
Any adverse events 165 (90.7%) 156 (85.7%)
Any infections 95 (52.2%) 93 (51.1%)
Any drug-related adverse events 19 (10.4%) 21 (11.5%)
Any drug-related infections 1 (0.5%)
Any serious adverse events 43 (23.6%) 45 (24.7%)
Any serious infections 11 (6.0%) 10 (5.5%)
Data are shown as number (% total).
DISCUSSION
This is the first study of adequate power to address
Fig. 1. Low-density lipoprotein-cholesterol (LDL-C) at 0, 2, 6 and 12 whether statin therapy is associated with a reduced acuteweeks. Symbols are () fluvastatin group; () control group. Data are
rejection rate following solid organ transplantation. Theshown as mean values. Significant differences (P  0.001) between the
groups from week 2. results demonstrate that whilst fluvastatin 40 mg per day
is effective in reducing total cholesterol and LDL-C, the
drug has no effect on the acute rejection rate, severity
of rejection or graft function during the first three months
There were no differences between treatment groups after renal transplantation.
and, specifically, there were no episodes of rhabdomyo- The study design was based on the results of two stud-
lysis. There were 16 reports of an elevation of creatinine ies in heart [13, 14] and one pilot study in renal [12]
kinase (CK) levels to more than five times the upper transplant recipients. The renal study showed a marked
limit of normal, nine in the fluvastatin and seven in the reduction (57%) in rejection episodes [12]. Of the two
placebo group, respectively. There were also 31 reported heart transplant studies, one showed no significant effect
increases in transaminase levels to more than three times on rejection rates [13], and the other only an effect on
the upper limit of normal, 11 of which were in the fluva- severe, but not mild-to-moderate rejection episodes or
statin group. These biochemical abnormalities required the overall rejection rate [14]. While the results of the
cessation of therapy in some cases. However, the number two studies indicating an effect suggest that statins may
of discontinuations due to drug-related side effects was have a role in preventing acute rejection in solid organ
similar in both groups. transplantation [12, 14], the studies were small and only
Basal immunosuppression. There were no differences one was designed to assess rejection rates [12]. Indeed,
between groups for cyclosporine A (CsA), prednisolone none of the studies were adequately powered to detect
or azathioprine dose throughout the study (Table 6). a significant reduction in this end point. There are num-
Blood pressure. Blood pressure values were similar in ber of possible explanations for the discrepancy between
both groups. At 12 weeks the mean systolic blood pres- the result of our study and those previously published.
sure was 145  18 versus 146  19 mm Hg (fluvastatin First, the published studies may be spuriously positive
vs. placebo, P  0.33) and the diastolic blood pressure due to small sample size and the differences reported
showed a similar pattern (85  11 vs. 86  13 mm Hg). may reflect other aspects of the study design or patient
Mean weight also showed no difference between groups, population. Second, the dose of fluvastatin used may
not be comparable to the doses of pravastatin used in76.0  11.5 vs. 74  12.9 kg at 12 weeks.
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Table 6. Basal immunosuppression
Baseline Week 2 Week 6 Week 12
F P F P F P F P
CsA mg/day 464192 475197 437185 426167 292161 304148 244131 243113
Prednisolone mg/day 3641 3337 2013 2018 176 1816 125 125
Azathioprine mg/day 11662 11457 8151 8245 6451 7149 6548 6749
Abbreviations are: CsA, cyclosporine A; F, fluvastatin; P, placebo.
previous studies. Finally, it is clearly possible that immu- present and previous studies [12–14]. Although cyclospo-
rine interacts with the metabolism of fluvastatin, the areanosuppressive actions are not common to all statins (flu-
vastatin, simvastatin), but specific to certain drugs of that under the curve for fluvastatin is increased only about
twofold during cyclosporine therapy [26]. In contrast,class (pravastatin).
concomitant cyclosporine increases the area under the
Study size and design curve several-fold for other statins [27]. The results of
this study confirm the predicted beneficial effects onThe single-center report by Katznelson et al in 48 renal
transplant patients, half were randomized to pravastatin the lipid profile in the post-transplant period. However,
these data are difficult to compare with outcome studies20 mg treatment [12]. The study did not have adequate
statistical power to detect a reduction in rejection epi- of statin therapy in the general population because of
the pattern of increasing levels of total cholesterol,sodes, and the very high rejection rate in the placebo
group (58%) suggests that this was not a representative LDL-C, and HDL-C and triglycerides that follow trans-
plantation. The key findings, based on the intention-to-study population. In contrast, the acute rejection rate in
our study is similar to that reported in other studies using treat analysis, show that LDL-C was 40.5% lower in the
fluvastatin group, compared with 26.3% [13] and 26.4%conventional cyclosporine-based double or triple therapy.
Moreover, although the number of rejection episodes [14] in the studies in cardiac transplantation and 27.8%
in the pilot study in renal transplant recipients [12] in(6 vs. 14) was significant at a 5% level in the study of
Katznelson et al [12], had a single additional rejection which beneficial effects on acute rejection were reported.
The comparison with other published studies is limitedepisode occurred in the active treatment group (7 vs. 13)
the findings would not have achieved statistical signifi- by the fact that previous studies reported the time-aver-
aged lipid levels during the follow-up period and thesecance. Thus, the failure of our present study, which has
greater statistical power to detect a reduction in acute are likely to decrease with reduction in immunosuppres-
sive therapy beyond three months, Thus, overall, fluvas-rejection rates, to confirm the earlier report in kidney
transplant recipients is likely to reflect the small size in tatin appears to have had a similar effect on LDL-C to
that observed in the other studies and the achieved levelthe previous report.
The reported study of cardiac transplant recipients dem- of mean LDL-C of around 3.1 mmol/L was similar to
that reported in the previous studies (2.8 to 3.0 mmol/L;onstrating a significant reduction in rejections included
fewer than 100 patients [14]. The improvement in rejec- [12–14]). Other lipid parameters also were modified by
active treatment. HDL-C was 5.2% higher, total choles-tion in this study was confined to severe, or hemodynami-
cally significant, rejection episodes with no effect on mild, terol was 18.3% lower and triglyceride 25.4% lower in
the fluvastatin group at three months post-transplant.moderate or focal moderate rejection episodes. Further-
more, it was designed to study regression of accelerated Moreover, the efficacy of fluvastatin in the present study
is diluted by the patients who failed to take therapygraft vascular disease (GVD) and not the incidence of
rejection episodes. However, the authors demonstrated a for the three-month follow-up period (Table 2). The
achieved levels of TC, HDL-C and TG show a similarsignificant reduction in intimal proliferation in the statin
treatment group in accordance with the study of Wenke pattern in comparison with other studies and are slightly
less than those reported for this dose of fluvastatin inet al [13]. Cardiac allograft rejection is more likely to
have hemodynamic sequelae in the presence of severe carefully controlled single-center studies in stable renal
transplant recipients [25, 27]. Thus, it seems unlikely aGVD and thus, the non-immunological effects of statins
on GVD, rather than any immunosuppressive effects may higher dose would have unmasked a significant effect on
rejection when none was apparent in the presence of aoffer an explanation for the effects on rejection severity
and patient survival. significant benefit on plasma lipids.
Is immunosuppression unique to other statins?Statin type and dosage
The choice of statin and dose equivalence may offer In vitro and in vivo studies have shown a variety of
effects of statins that appear to be mediated by interme-alternative explanations for the discrepancy between the
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